An in silico study: Novel targets for potential drug and vaccine design against drug resistant H. pylori

Gastric cancer risk and adverse ramifications by augmented multi-drug resistance (MDR) of Helicobacter pylori are alarming serious health concern. Combating through available drugs is a difficult task due to lack of appropriate common targets against genetically diverse strains. To improve efficacy,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Microbial pathogenesis 2018-09, Vol.122, p.156-161
Hauptverfasser: Pasala, Chiranjeevi, Chilamakuri, Chandra Sekhar Reddy, Katari, Sudheer Kumar, Nalamolu, Ravina Madhulitha, Bitla, Aparna R., Umamaheswari, Amineni
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 161
container_issue
container_start_page 156
container_title Microbial pathogenesis
container_volume 122
creator Pasala, Chiranjeevi
Chilamakuri, Chandra Sekhar Reddy
Katari, Sudheer Kumar
Nalamolu, Ravina Madhulitha
Bitla, Aparna R.
Umamaheswari, Amineni
description Gastric cancer risk and adverse ramifications by augmented multi-drug resistance (MDR) of Helicobacter pylori are alarming serious health concern. Combating through available drugs is a difficult task due to lack of appropriate common targets against genetically diverse strains. To improve efficacy, the effective targets should be identified and critically assessed. In the present study, we aim to predict the potential novel targets against H. pylori strains by employing computer aided approach. The genomic dataset of 53 H. pylori strains was comparatively processed and eventually predicted 826 ‘conserved gene products’. Further, we performed subtractive genomic approach in search of promising crucial targets through the combination of in silico analyses. Codon adaptation index (CAI) value calculation and literature surveys were also done in order to find highly expressed gene products with novelty. Consequently, four enzymes and three membrane proteins were prioritized as new therapeutic and vaccine targets respectively which found to have more interactors in network with high-confidence score, druggability, antigenicity and molecular weight
doi_str_mv 10.1016/j.micpath.2018.05.037
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2045306073</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0882401017308902</els_id><sourcerecordid>2045306073</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-78a6e2e1d6c9e42dda5638ef31b90f63e2876d485a21d14471b921078a27e9723</originalsourceid><addsrcrecordid>eNqFkEFP3DAQha0KVLa0PwHkI5ekYztxHC4IoVIqoXJpz5axJ4tXWTvYzkr77xu0C9eeRnrz3jzNR8gFg5oBk9839dbbyZSXmgNTNbQ1iO4TWTHoZcU4qBOyAqV41QCDM_Il5w0A9I3oP5Mz3isA2csVebkN1Aea_ehtpLnMbn9Nf8cdjrSYtMaS6RATnWLBULwZqUvzmprg6M5Y6wNSh9mvAzVr40Muh31atFxMKPShptN-jMl_JaeDGTN-O85z8vf-x5-7h-rx6eevu9vHygrZlqpTRiJH5qTtseHOmVYKhYNgzz0MUiBXnXSNag1njjVNt-icwRLjHfYdF-fk6nB3SvF1xlz01meL42gCxjlrDk0rQEInFmt7sNoUc0446Cn5rUl7zUC_QdYbfYSs3yBraPUCecldHivm5y26j9Q71cVwczDg8ujOY9LZegwWnU9oi3bR_6fiHx-vkDo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2045306073</pqid></control><display><type>article</type><title>An in silico study: Novel targets for potential drug and vaccine design against drug resistant H. pylori</title><source>Elsevier ScienceDirect Journals</source><creator>Pasala, Chiranjeevi ; Chilamakuri, Chandra Sekhar Reddy ; Katari, Sudheer Kumar ; Nalamolu, Ravina Madhulitha ; Bitla, Aparna R. ; Umamaheswari, Amineni</creator><creatorcontrib>Pasala, Chiranjeevi ; Chilamakuri, Chandra Sekhar Reddy ; Katari, Sudheer Kumar ; Nalamolu, Ravina Madhulitha ; Bitla, Aparna R. ; Umamaheswari, Amineni</creatorcontrib><description>Gastric cancer risk and adverse ramifications by augmented multi-drug resistance (MDR) of Helicobacter pylori are alarming serious health concern. Combating through available drugs is a difficult task due to lack of appropriate common targets against genetically diverse strains. To improve efficacy, the effective targets should be identified and critically assessed. In the present study, we aim to predict the potential novel targets against H. pylori strains by employing computer aided approach. The genomic dataset of 53 H. pylori strains was comparatively processed and eventually predicted 826 ‘conserved gene products’. Further, we performed subtractive genomic approach in search of promising crucial targets through the combination of in silico analyses. Codon adaptation index (CAI) value calculation and literature surveys were also done in order to find highly expressed gene products with novelty. Consequently, four enzymes and three membrane proteins were prioritized as new therapeutic and vaccine targets respectively which found to have more interactors in network with high-confidence score, druggability, antigenicity and molecular weight &lt;110 kDa. Therefore, our results underpin the importance of new targets may counteract with false–positive/negatives and facilitate appropriate potential targets for a new insight of reliable therapeutic development. •R-programming scripts based comparative analysis of 53 H. pylori strains resulted in a dataset of 826 common proteins.•An attenuated subtractive proteomics approach yielded the optimized 18 putative drug and four vaccine common targets.•Codon adaptation index value calculation revealed 16 of 18 enzymes as highly expressed targets and considered as potential.•Target exploration through literature survey has given three drug and four vaccine novel target.•These consequences could help in making the best choices for developing better common therapeutics against multiple strains.</description><identifier>ISSN: 0882-4010</identifier><identifier>EISSN: 1096-1208</identifier><identifier>DOI: 10.1016/j.micpath.2018.05.037</identifier><identifier>PMID: 29800696</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Common proteins ; Druggability ; H. pylori ; Metabolic pathways ; Network analysis ; Therapeutic targets</subject><ispartof>Microbial pathogenesis, 2018-09, Vol.122, p.156-161</ispartof><rights>2018</rights><rights>Copyright © 2018. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-78a6e2e1d6c9e42dda5638ef31b90f63e2876d485a21d14471b921078a27e9723</citedby><cites>FETCH-LOGICAL-c365t-78a6e2e1d6c9e42dda5638ef31b90f63e2876d485a21d14471b921078a27e9723</cites><orcidid>0000-0002-4345-2141</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0882401017308902$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29800696$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pasala, Chiranjeevi</creatorcontrib><creatorcontrib>Chilamakuri, Chandra Sekhar Reddy</creatorcontrib><creatorcontrib>Katari, Sudheer Kumar</creatorcontrib><creatorcontrib>Nalamolu, Ravina Madhulitha</creatorcontrib><creatorcontrib>Bitla, Aparna R.</creatorcontrib><creatorcontrib>Umamaheswari, Amineni</creatorcontrib><title>An in silico study: Novel targets for potential drug and vaccine design against drug resistant H. pylori</title><title>Microbial pathogenesis</title><addtitle>Microb Pathog</addtitle><description>Gastric cancer risk and adverse ramifications by augmented multi-drug resistance (MDR) of Helicobacter pylori are alarming serious health concern. Combating through available drugs is a difficult task due to lack of appropriate common targets against genetically diverse strains. To improve efficacy, the effective targets should be identified and critically assessed. In the present study, we aim to predict the potential novel targets against H. pylori strains by employing computer aided approach. The genomic dataset of 53 H. pylori strains was comparatively processed and eventually predicted 826 ‘conserved gene products’. Further, we performed subtractive genomic approach in search of promising crucial targets through the combination of in silico analyses. Codon adaptation index (CAI) value calculation and literature surveys were also done in order to find highly expressed gene products with novelty. Consequently, four enzymes and three membrane proteins were prioritized as new therapeutic and vaccine targets respectively which found to have more interactors in network with high-confidence score, druggability, antigenicity and molecular weight &lt;110 kDa. Therefore, our results underpin the importance of new targets may counteract with false–positive/negatives and facilitate appropriate potential targets for a new insight of reliable therapeutic development. •R-programming scripts based comparative analysis of 53 H. pylori strains resulted in a dataset of 826 common proteins.•An attenuated subtractive proteomics approach yielded the optimized 18 putative drug and four vaccine common targets.•Codon adaptation index value calculation revealed 16 of 18 enzymes as highly expressed targets and considered as potential.•Target exploration through literature survey has given three drug and four vaccine novel target.•These consequences could help in making the best choices for developing better common therapeutics against multiple strains.</description><subject>Common proteins</subject><subject>Druggability</subject><subject>H. pylori</subject><subject>Metabolic pathways</subject><subject>Network analysis</subject><subject>Therapeutic targets</subject><issn>0882-4010</issn><issn>1096-1208</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFkEFP3DAQha0KVLa0PwHkI5ekYztxHC4IoVIqoXJpz5axJ4tXWTvYzkr77xu0C9eeRnrz3jzNR8gFg5oBk9839dbbyZSXmgNTNbQ1iO4TWTHoZcU4qBOyAqV41QCDM_Il5w0A9I3oP5Mz3isA2csVebkN1Aea_ehtpLnMbn9Nf8cdjrSYtMaS6RATnWLBULwZqUvzmprg6M5Y6wNSh9mvAzVr40Muh31atFxMKPShptN-jMl_JaeDGTN-O85z8vf-x5-7h-rx6eevu9vHygrZlqpTRiJH5qTtseHOmVYKhYNgzz0MUiBXnXSNag1njjVNt-icwRLjHfYdF-fk6nB3SvF1xlz01meL42gCxjlrDk0rQEInFmt7sNoUc0446Cn5rUl7zUC_QdYbfYSs3yBraPUCecldHivm5y26j9Q71cVwczDg8ujOY9LZegwWnU9oi3bR_6fiHx-vkDo</recordid><startdate>201809</startdate><enddate>201809</enddate><creator>Pasala, Chiranjeevi</creator><creator>Chilamakuri, Chandra Sekhar Reddy</creator><creator>Katari, Sudheer Kumar</creator><creator>Nalamolu, Ravina Madhulitha</creator><creator>Bitla, Aparna R.</creator><creator>Umamaheswari, Amineni</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4345-2141</orcidid></search><sort><creationdate>201809</creationdate><title>An in silico study: Novel targets for potential drug and vaccine design against drug resistant H. pylori</title><author>Pasala, Chiranjeevi ; Chilamakuri, Chandra Sekhar Reddy ; Katari, Sudheer Kumar ; Nalamolu, Ravina Madhulitha ; Bitla, Aparna R. ; Umamaheswari, Amineni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-78a6e2e1d6c9e42dda5638ef31b90f63e2876d485a21d14471b921078a27e9723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Common proteins</topic><topic>Druggability</topic><topic>H. pylori</topic><topic>Metabolic pathways</topic><topic>Network analysis</topic><topic>Therapeutic targets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pasala, Chiranjeevi</creatorcontrib><creatorcontrib>Chilamakuri, Chandra Sekhar Reddy</creatorcontrib><creatorcontrib>Katari, Sudheer Kumar</creatorcontrib><creatorcontrib>Nalamolu, Ravina Madhulitha</creatorcontrib><creatorcontrib>Bitla, Aparna R.</creatorcontrib><creatorcontrib>Umamaheswari, Amineni</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Microbial pathogenesis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pasala, Chiranjeevi</au><au>Chilamakuri, Chandra Sekhar Reddy</au><au>Katari, Sudheer Kumar</au><au>Nalamolu, Ravina Madhulitha</au><au>Bitla, Aparna R.</au><au>Umamaheswari, Amineni</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An in silico study: Novel targets for potential drug and vaccine design against drug resistant H. pylori</atitle><jtitle>Microbial pathogenesis</jtitle><addtitle>Microb Pathog</addtitle><date>2018-09</date><risdate>2018</risdate><volume>122</volume><spage>156</spage><epage>161</epage><pages>156-161</pages><issn>0882-4010</issn><eissn>1096-1208</eissn><abstract>Gastric cancer risk and adverse ramifications by augmented multi-drug resistance (MDR) of Helicobacter pylori are alarming serious health concern. Combating through available drugs is a difficult task due to lack of appropriate common targets against genetically diverse strains. To improve efficacy, the effective targets should be identified and critically assessed. In the present study, we aim to predict the potential novel targets against H. pylori strains by employing computer aided approach. The genomic dataset of 53 H. pylori strains was comparatively processed and eventually predicted 826 ‘conserved gene products’. Further, we performed subtractive genomic approach in search of promising crucial targets through the combination of in silico analyses. Codon adaptation index (CAI) value calculation and literature surveys were also done in order to find highly expressed gene products with novelty. Consequently, four enzymes and three membrane proteins were prioritized as new therapeutic and vaccine targets respectively which found to have more interactors in network with high-confidence score, druggability, antigenicity and molecular weight &lt;110 kDa. Therefore, our results underpin the importance of new targets may counteract with false–positive/negatives and facilitate appropriate potential targets for a new insight of reliable therapeutic development. •R-programming scripts based comparative analysis of 53 H. pylori strains resulted in a dataset of 826 common proteins.•An attenuated subtractive proteomics approach yielded the optimized 18 putative drug and four vaccine common targets.•Codon adaptation index value calculation revealed 16 of 18 enzymes as highly expressed targets and considered as potential.•Target exploration through literature survey has given three drug and four vaccine novel target.•These consequences could help in making the best choices for developing better common therapeutics against multiple strains.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29800696</pmid><doi>10.1016/j.micpath.2018.05.037</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-4345-2141</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0882-4010
ispartof Microbial pathogenesis, 2018-09, Vol.122, p.156-161
issn 0882-4010
1096-1208
language eng
recordid cdi_proquest_miscellaneous_2045306073
source Elsevier ScienceDirect Journals
subjects Common proteins
Druggability
H. pylori
Metabolic pathways
Network analysis
Therapeutic targets
title An in silico study: Novel targets for potential drug and vaccine design against drug resistant H. pylori
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T16%3A53%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20in%20silico%20study:%20Novel%20targets%20for%20potential%20drug%20and%20vaccine%20design%20against%20drug%20resistant%20H.%20pylori&rft.jtitle=Microbial%20pathogenesis&rft.au=Pasala,%20Chiranjeevi&rft.date=2018-09&rft.volume=122&rft.spage=156&rft.epage=161&rft.pages=156-161&rft.issn=0882-4010&rft.eissn=1096-1208&rft_id=info:doi/10.1016/j.micpath.2018.05.037&rft_dat=%3Cproquest_cross%3E2045306073%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2045306073&rft_id=info:pmid/29800696&rft_els_id=S0882401017308902&rfr_iscdi=true